Changes in left ventricular geometry during antihypertensive treatment. 2018

Massimo Salvetti, and Anna Paini, and Fabio Bertacchini, and Deborah Stassaldi, and Carlo Aggiusti, and Claudia Agabiti Rosei, and Davide Bassetti, and Enrico Agabiti-Rosei, and Maria Lorenza Muiesan
Department of Clinical and Experimental Sciences, University of Brescia, 2a Medicina ASST Spedali Civili di Brescia, Italy and Società Italiana dell'Ipertensione Arteriosa.

The reduction of echocardiographic left ventricular (LV) mass and the change toward a less concentric geometry during antihypertensive treatment are independently associated with a better prognosis. Blood pressure-lowering treatment may reduce cardiac hypertrophy, although different effect on changes of LV mass have been reported among antihypertensive drug classes, while changes in echocardiographic evaluated LV geometry have not been systemically evaluated. It is not yet clear whether antihypertensive drugs may influence LV geometry. Our aim was to compare the effects of diuretics (D), beta-blockers (BB), calcium channel blockers (CCB), angiotensin-converting enzyme inhibitors (ACE-I), and angiotensin receptor blockers (ARBS) on relative wall thickness (RWT) in patients with hypertension on the basis of prospective, randomized comparative studies. MEDLINE, and the ISI Web of Sciences were searched for randomized clinical trials evaluating LV mass and geometry at baseline and end follow-up. We have performed a pooled pairwise comparisons of the effect of the 5 major drug classes on relative wall thickness changes, and of each drug class versus other classes statistically combined. We selected 53 publications involving 7684 patients. A significant correlation was observed between percent changes from baseline to end of treatment in LV mass and those in systolic BP (r = 0.44, p < 0.001). Reduction of LV mass was significantly greater with CCB than with BB (P <  0.02) without other significant differences between drug classes. Percent changes in RWT were related to percent changes in LV mass/LVmass index (r = 0.68, p = 0.016) and of SBP (r = 0.64 p < 0.033). RWT decreased during treatment with all classes of drugs, except the combination of BB and D; the decrease of RWT was less with diuretics and sympatholytic drugs. In studies evaluating the effect of different classes of antihypertensive drugs on LV mass, the reduction of relative wall thickness seems to be less during treatment with diuretics.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

Massimo Salvetti, and Anna Paini, and Fabio Bertacchini, and Deborah Stassaldi, and Carlo Aggiusti, and Claudia Agabiti Rosei, and Davide Bassetti, and Enrico Agabiti-Rosei, and Maria Lorenza Muiesan
December 2011, Pediatric nephrology (Berlin, Germany),
Massimo Salvetti, and Anna Paini, and Fabio Bertacchini, and Deborah Stassaldi, and Carlo Aggiusti, and Claudia Agabiti Rosei, and Davide Bassetti, and Enrico Agabiti-Rosei, and Maria Lorenza Muiesan
August 1987, Journal of applied physiology (Bethesda, Md. : 1985),
Massimo Salvetti, and Anna Paini, and Fabio Bertacchini, and Deborah Stassaldi, and Carlo Aggiusti, and Claudia Agabiti Rosei, and Davide Bassetti, and Enrico Agabiti-Rosei, and Maria Lorenza Muiesan
August 2013, Journal of hypertension,
Massimo Salvetti, and Anna Paini, and Fabio Bertacchini, and Deborah Stassaldi, and Carlo Aggiusti, and Claudia Agabiti Rosei, and Davide Bassetti, and Enrico Agabiti-Rosei, and Maria Lorenza Muiesan
January 1992, The Clinical investigator,
Massimo Salvetti, and Anna Paini, and Fabio Bertacchini, and Deborah Stassaldi, and Carlo Aggiusti, and Claudia Agabiti Rosei, and Davide Bassetti, and Enrico Agabiti-Rosei, and Maria Lorenza Muiesan
October 2004, Pharmacoepidemiology and drug safety,
Massimo Salvetti, and Anna Paini, and Fabio Bertacchini, and Deborah Stassaldi, and Carlo Aggiusti, and Claudia Agabiti Rosei, and Davide Bassetti, and Enrico Agabiti-Rosei, and Maria Lorenza Muiesan
August 2006, Acta cardiologica,
Massimo Salvetti, and Anna Paini, and Fabio Bertacchini, and Deborah Stassaldi, and Carlo Aggiusti, and Claudia Agabiti Rosei, and Davide Bassetti, and Enrico Agabiti-Rosei, and Maria Lorenza Muiesan
November 1995, Journal of cardiovascular pharmacology,
Massimo Salvetti, and Anna Paini, and Fabio Bertacchini, and Deborah Stassaldi, and Carlo Aggiusti, and Claudia Agabiti Rosei, and Davide Bassetti, and Enrico Agabiti-Rosei, and Maria Lorenza Muiesan
March 2011, Vnitrni lekarstvi,
Massimo Salvetti, and Anna Paini, and Fabio Bertacchini, and Deborah Stassaldi, and Carlo Aggiusti, and Claudia Agabiti Rosei, and Davide Bassetti, and Enrico Agabiti-Rosei, and Maria Lorenza Muiesan
April 1957, American heart journal,
Massimo Salvetti, and Anna Paini, and Fabio Bertacchini, and Deborah Stassaldi, and Carlo Aggiusti, and Claudia Agabiti Rosei, and Davide Bassetti, and Enrico Agabiti-Rosei, and Maria Lorenza Muiesan
January 1994, Blood pressure. Supplement,
Copied contents to your clipboard!